Clinical Trial Update: Epcoritamab in Previously Treated WM [Phase 2]

View source ↗

Summary

Epcoritamab is being studied in a Phase 2 trial for patients with Waldenström macroglobulinemia who have received prior treatment; the study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoproliferative Disorder
• Waldenström Macroglobulinemia

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Gottfried von Keudell, MD PhD | Conditions: Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder | Phase 2 | Status: RECRUITING